{"disease":{"id":"herpes-simplex-keratitis","name":"Herpes simplex keratitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"vidarabine","indication_name":"Herpes simplex dendritic keratitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidarabin","generic_name":"VIDARABINE","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"vidarabine","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"vidarabine","indication_name":"Herpes simplex keratitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidarabin","generic_name":"VIDARABINE","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"vidarabine","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"Herpes simplex dendritic keratitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"idoxuridine","indication_name":"Herpes simplex keratitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dendrid","generic_name":"IDOXURIDINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thymidine kinase, cytosolic","drug_class":"Nucleoside Analog Antiviral","quality_score":30,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03217474","title":"Femtosecond Laser-assisted Corneal Debridement for Herpes Simplex Keratitis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Chunxiao Wang","has_results":false},{"nct_id":"NCT00001648","title":"Structure of the Herpes Simplex Virus Receptor","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03626376","title":"Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"NYU Langone Health","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}